Research progress of furmonertinib for <italic style="font-style: italic">EGFR</italic>-mutated non-small cell lung cancer

GU Hangye; LYU Qing; CHEN Yong

doi:10.6039/j.issn.1001-0408.2023.14.23

您当前的位置：

首页 >

文章列表页 >

Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer

更新时间：2023-07-24

- Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer
- ZHONGGUO YAOFANG Vol. 34, Issue 14, Pages: 1788-1792(2023)
- 作者机构：
  
  广东药科大学附属第一医院临床药学重点专科，广州　510000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.14.23
  CLC： R965
- Published：30 July 2023，
  
  Received：21 February 2023，
  
  Revised：21 June 2023，
扫描看全文
顾航烨,吕晴,陈永.伏美替尼治疗EGFR基因突变非小细胞肺癌的研究进展^Δ[J].中国药房,2023,34(14):1788-1792.

GU Hangye,LYU Qing,CHEN Yong.Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer[J].ZHONGGUO YAOFANG,2023,34(14):1788-1792.
顾航烨,吕晴,陈永.伏美替尼治疗EGFR基因突变非小细胞肺癌的研究进展^Δ[J].中国药房,2023,34(14):1788-1792. DOI： 10.6039/j.issn.1001-0408.2023.14.23.

GU Hangye,LYU Qing,CHEN Yong.Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer[J].ZHONGGUO YAOFANG,2023,34(14):1788-1792. DOI： 10.6039/j.issn.1001-0408.2023.14.23.

摘要

肺癌以非小细胞肺癌（NSCLC）为主，而NSCLC常伴有表皮生长因子受体（

EGFR

）基因突变。目前，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）是一线治疗

EGFR

基因突变NSCLC的优选方案。伏美替尼是国内第2个上市的由我国自主研发的第三代EGFR-TKI。本文综述结果显示，伏美替尼具有双重活性、强抑瘤性、高选择性和高安全性等特点，对

EGFR

敏感突变、

EGFR

20号外显子T790M耐药突变、

EGFR

20号外显子插入突变以及中枢神经系统转移NSCLC患者疗效确切，且其相关临床试验均仅入组我国患者，对我国NSCLC患者的治疗更具指导意义。

Abstract

Lung cancer is mainly non-small cell lung cancer （NSCLC）. NSCLC is often associated with epidermal growth factor receptor （

EGFR

） gene mutations. Currently， epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKI） are the preferred first-line treatment option for

EGFR

-mutated NSCLC. Furmonertinib is the second third-generation EGFR-TKI marketed in China， which is developed independently by China. In this review， it is found that furmonertinib has dual activity， strong tumor suppression， high selectivity， and high safety profile， and is effective in the treatment of

EGFR

-sensitive mutation，

EGFR

exon 20 T790M resistance mutation，

EGFR

exon 20 insertion mutation， and central nervous system metastasis NSCLC， and its relevant clinical trials are only enrolled in Chinese patients， which is more guidance for Chinese NSCLC patients in China.

关键词

伏美替尼表皮生长因子受体酪氨酸激酶抑制剂非小细胞肺癌突变有效性安全性

Keywords

epidermal growth factor receptortyrosine kinase inhibitorsnon-small cell lung cancermutationsefficacysafety

references

国家卫生健康委员会. 原发性肺癌诊疗指南：2022年版[J]. 中国合理用药探索，2022，19（9）：1-28.

MIDHA A，DEARDEN S，MCCORMACK R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology：a systematic review and global map by ethnicity（mutMapⅡ）[J]. Am J Cancer Res，2015，5（9）：2892-2911.

邓洪森. 非小细胞肺癌临床病理特点与基因突变位点频率的回顾分析[D]. 遵义：遵义医科大学，2022.

ZHANG T L，WAN B，ZHAO Y，et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer：new evidence and treatment[J]. Transl Lung Cancer Res，2019，8（3）：302-316.

LIANG Y，ZHANG T H，ZHANG J. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor：their relevance for cancer therapy[J]. Pharmacol Res，2020，161：105164.

官绍年，陈迎珠，卓明磊，等. 非小细胞肺癌EGFR基因突变检测的临床应用进展[J]. 临床检验杂志，2020，38（2）：130-136.

UNNISA A，CHETTUPALLI A K，HUSSAIN T，et al. Recent advances in epidermal growth factor receptor inhibitors（EGFRIs）and their role in the treatment of cancer：a review[J]. Anticancer Agents Med Chem，2022，22（20）：3370-3381.

SHI Y K，ZHANG S C，HU X S，et al. Safety，clinical activity，and pharmacokinetics of alflutinib（AST2818）in patients with advanced NSCLC with EGFR T790M mutation[J]. J Thorac Oncol，2020，15（6）：1015-1026.

ZHOU C，XIE L J，LIU W，et al. Absorption，metabolism，excretion，and safety of [14C] almonertinib in healthy Chinese subjects[J]. Ann Transl Med，2021，9（10）：867.

ZHU Y T，ZHANG Y F，JIANG J F，et al. Effects of rifampicin on the pharmacokinetics of alflutinib，a selective third-generation EGFR kinase inhibitor，and its metabolite AST5902 in healthy volunteers[J]. Invest New Drugs，2021，39（4）：1011-1018.

HENG J F，TANG Q，CHEN X，et al. Evaluation of the pharmacokinetic effects of itraconazole on alflutinib（AST2818）：an open-label，single-center，single-sequence，two-period randomized study in healthy volunteers[J]. Eur J Pharm Sci，2021，162：105815.

SHI Y K，HU X S，ZHANG S C，et al. Efficacy，safety，and genetic analysis of furmonertinib（AST2818）in patients with EGFR T790M mutated non-small-cell lung cancer：a phase 2b，multicentre，single-arm，open-label study[J]. Lancet Respir Med，2021，9（8）：829-839.

黄珺霞，王红. 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制[J]. 中国肺癌杂志，2022，25（3）：183-192.

SHI Y K，CHEN G Y，WANG X，et al. Furmonertinib（AST2818）versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer（FURLONG）：a multicentre，double-blind，randomised phase 3 study[J]. Lancet Respir Med，2022，10（11）：1019-1028.

SHI Y K，CHEN G Y，WANG X，et al. Central nervous system efficacy of furmonertinib（AST2818）versus gefitinib as first-line treatment for EGFR-mutated NSCLC：results from the FURLONG study[J]. J Thorac Oncol，2022，17（11）：1297-1305.

BURNETT H，EMICH H，CARROLL C，et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer：a systematic literature review[J]. PLoS One，2021，16（3）：e0247620.

HAN B，ZHOU C，WU L，et al. Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions（20ins）[J]. Ann Oncol，2021，32：S964.

SORIA J C，OHE Y，VANSTEENKISTE J，et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med，2018，378（2）：113-125.

CHENG Y，HE Y，LI W，et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated（EGFRm） advanced NSCLC：FLAURA China study overall survival（OS）[J]. Ann Oncol，2020，31：S838-S839.

LU S，DONG X R，JIAN H，et al. AENEAS：a rando-mized phase Ⅲ trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations[J]. J Clin Oncol，2022，40（27）：3162-3171.

KIM T M，OCK C Y，KIM M，et al. Phase Ⅱ study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation：a multicenter trial of the Korean Cancer Study Group（LU17-19）[J]. Ann Oncol，2019，30：v628.

YASUDA H，ICHIHARA E，SAKAKIBARA-KONISHI J，et al. A phase Ⅰ/Ⅱ study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer[J]. Lung Cancer，2021，162：140-146.

PIOTROWSKA Z，WANG Y T，SEQUIST L，et al. ECOG-ACRIN 5162：a phase Ⅱ study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions[J]. J Clin Oncol，2020，38（15_suppl）：9513.

ZWIERENGA F，VAN VEGGEL B，HENDRIKS L E L，et al. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC：results from the phase 2 multicenter POSITION20 trial[J]. Lung Cancer，2022，170：133-140.

崔久嵬，段建春，任胜祥，等. 三代EGFR-TKI在EGFR突变NSCLC治疗中应用的专家共识：2022年版[J]. 中国肺癌杂志，2022，25（9）：627-641.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy

Efficacy and safety of aerosol inhalation of polycolistin B in patients with severe pneumonia combined with mechanical ventilation

Efficacy and safety of olaparib in adjuvant therapy of BRCA1/2 mutated HER2-negative breast cancer： a meta-analysis

Efficacy and safety of parecoxib versus ketorolac tromethamine for perioperative analgesia： a systematic review

Efficacy and safety of levetiracetam versus valproic acid in the treatment of pediatric epilepsy： a meta analysis

Related Author

GUO Xiaqing

LI Guofei

SUN Yuhua

ZHENG Donglin

YANG Yilei

ZHANG Hu

CAO Jia

YI Qiaoyan

Related Institution

First Ward， Dept. of Neurology， Huaihe Hospital of Henan University

Center for Big Data Research in Health and Medicine， the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Dept. of Clinical Pharmacy， the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital， Shandong Engineering and Technology Research Center for Pediatric Drug Development， Shandong Medicine and Health Key Laboratory of Clinical Pharmacy

Dept. of Pharmacy， Harbin Medical University Cancer Hospital

Department of Pharmacy，Sichuan Clinical Research Center for Cancer/Sichuan Cancer Hospital & Institute/Sichuan Cancer Center/Affiliated Cancer Hospital of University of Electronic Science and Technology of China

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer

DOI：10.6039/j.issn.1001-0408.2023.14.23

摘要

Abstract

关键词

Keywords

references